Apolipoprotein A-IV acts centrally in the brain to reduce the severity of gastric ulceration in the rat.
We have recently reported that apolipoprotein A-IV (apo A-IV), a protein associated with lipoproteins, acts in the brain to inhibit gastric acid secretion. In the present study, we determined whether or not apo A-IV has an anti-ulcer action via the central nervous system using Sprague-Dawley rats. Intracisternal injection of apo A-IV dose-dependently (2.0-4.0 micrograms/rat) reduced the severity of gastric mucosal lesions induced by intravenous injection of 2-deoxy-D-glucose or subcutaneous administration of indomethacine. A higher dose (15 micrograms) of apo A-IV injected intraperitoneally failed to inhibit the development of gastric mucosal damage evoked by these ulcerogenic agents. These results suggest for the first time that apo A-IV has an anti-ulcer action through a central mechanism.
Okumura
T
T
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Taylor
I L
IL
Fukagawa
K
K
Tso
P
P
Pappas
T N
TN
D000818:Animals; D001054:Apolipoproteins A / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000502:physiology; D003847:Deoxyglucose; D004305:Dose-Response Relationship, Drug; D007213:Indomethacin; D007278:Injections, Spinal; D008297:Male; D010437:Peptic Ulcer / Q000139:chemically induced* / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley
D001054:Apolipoproteins A; C022205:apolipoprotein A-IV; D003847:Deoxyglucose; D007213:Indomethacin